Trevi Therapeutics, Inc.·4

Jun 21, 4:00 PM ET

Simon Farrell 4

4 · Trevi Therapeutics, Inc. · Filed Jun 21, 2023

Insider Transaction Report

Form 4
Period: 2023-06-20
Simon Farrell
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-06-20$0.51/sh+6,250$3,19445,650 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2023-06-206,25050,000 total
    Exercise: $0.51Exp: 2032-02-10Common Stock (6,250 underlying)
Footnotes (1)
  • [F1]This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION